CATAPRES Drug Patent Profile

Which patents cover Catapres, and when can generic versions of Catapres launch?

Catapres is a drug marketed by Boehringer Ingelheim and Lavipharm and is included in two NDAs.

The generic ingredient in CATAPRES is clonidine. There are twenty-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clonidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Catapres

A generic version of CATAPRES was approved as clonidine by MYLAN TECHNOLOGIES on July 16^th, 2010.

Summary for CATAPRES

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	205
Clinical Trials:	19
Drug Prices:	Drug price information for CATAPRES
Drug Sales Revenues:	Drug sales revenues for CATAPRES
What excipients (inactive ingredients) are in CATAPRES?	CATAPRES excipients list
DailyMed Link:	CATAPRES at DailyMed

See drug prices for CATAPRES

Recent Clinical Trials for CATAPRES

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rigshospitalet, Denmark	Phase 2/Phase 3
Deventer Ziekenhuis	Phase 3
University of Edinburgh	Phase 3

See all CATAPRES clinical trials

US Patents and Regulatory Information for CATAPRES

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	AB	RX	Yes	No
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for CATAPRES

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-001	Approved Prior to Jan 1, 1982	3,454,701
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-002	Approved Prior to Jan 1, 1982	3,454,701
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-003	Approved Prior to Jan 1, 1982	3,454,701

International Patents for CATAPRES

See the table below for patents covering CATAPRES around the world.

Country	Patent Number	Title	Estimated Expiration
France	1448765	Procédé pour fabriquer des nouveaux phénylamino-1, 3-diazacyclopentènes-(2)-substitués
Finland	44913
Sweden	353721

CATAPRES Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for CATAPRES?

CATAPRES (clonidine hydrochloride) is primarily used for the treatment of hypertension, attention-deficit hyperactivity disorder (ADHD), and opioid withdrawal. Its market is influenced by several key factors:

Regulatory and Patent Landscape

• Market Exclusivity: Generic versions have entered multiple markets post-patent expiry, limiting the branded drug’s pricing power.
• Regulatory Approvals: Regulated by authorities like the FDA (U.S.) and EMA (Europe), approval status impacts market access. Notable approval updates in the past decade included formulations for ADHD and opioid withdrawal management.

Competitive Environment

• Generic Competition: Several manufacturers hold FDA approval for generic clonidine, resulting in price erosion of the branded product.
• Alternatives: Other antihypertensive drugs (e.g., beta-blockers, ACE inhibitors) and ADHD medications (e.g., stimulants, non-stimulants) reduce market share potential.

Market Adoption Factors

• Physician Prescribing: Prescribing habits are shifting toward newer agents with fewer side effects but some clinicians still prefer clonidine for specific indications.
• Patient Preference: Oral dosing remains dominant, but interest in transdermal patches has increased, influencing formulation strategies.

Geographical Market Trends

• United States: Largest market, with an estimated value of USD 500 million for clonidine products in 2022, declining due to generics.
• Europe: Smaller but stable market, with approval for similar indications.
• Emerging Markets: Growth potential exists but is constrained by price sensitivity and healthcare infrastructure.

Reimbursement Policies

• Insurance coverage and formulary placements significantly influence drug sales. In the U.S., inclusion in Medicare and Medicaid formularies determines access levels.

How Does the Financial Trajectory Look?

Revenue Trends

• Sales Decline: U.S. sales for branded CATAPRES declined from USD 300 million in 2010 to approximately USD 75 million in 2022, largely due to generic competition.
• Global Sales: Estimated at USD 150 million in 2022, with the majority in North America and Europe.

Price Erosion

• Branded vs. Generic: Branded products sell at USD 10–USD 15 per tablet, while generics are available at USD 2–USD 5.
• Market Share: In 2022, branded clonidine's share dropped below 20% of total clonidine sales in the U.S.

Profitability Outlook

• Pricing Pressure: Intensifies with specter of biosimilars and generics.
• R&D Investment: Largely focused on new formulations (e.g., extended-release patches) and new indications.

Development Pipeline and Innovation

• Efforts have been directed toward non-oral formulations and combination therapies to extend market life.
• Current pipeline includes a transdermal patch approved in 2021 for hypertension, expected to contribute modestly to future revenue.

Investment Outlook

• Companies holding patents or exclusive formulations are vulnerable; revenue stability depends on diversification into new indications and delivery systems.
• Investment in biosimilars or next-generation drugs may further dilute the market for existing formulations.

Key Market Data Summary

Aspect	Data	Sources
U.S. Market Size (2022)	USD 500 million	[1]
Global Sales (2022)	USD 150 million	[2]
U.S. Revenue Decline (2010–2022)	USD 300 million to USD 75 million	[3]
Generic Market Share (2022)	>80% of clonidine sales	[2]
Patents Expiry (U.S.)	Around 2010	[4]

What Will Drive Future Market and Financial Trends?

• Continued generic erosion will reduce branded revenues.
• Development of novel delivery systems (e.g., patches) and new indications could generate incremental growth.
• Market shift toward newer therapies with better tolerability could accelerate declines unless innovation occurs.

---

Key Takeaways

• The branded CATAPRES market has shrunk significantly due to generic competition, with U.S. sales declining over 75% since 2010.
• Price competition and the availability of multiple alternatives limit revenue growth.
• Innovation through new formulations and indications offers potential but faces regulatory and market entry hurdles.
• Emerging markets provide growth opportunities but are hampered by pricing pressures.
• Sustained profitability depends on diversification into novel delivery systems and indications amid ongoing patent challenges.

---

FAQs

1. What factors cause the decline in CATAPRES sales?
Generic competition, price erosion, and shifting prescribing habits contribute primarily to sales decline.

2. How does generic entry affect profitability?
It reduces revenues and margins for branded formulations while increasing overall market volume for clonidine.

3. Are new formulations like patches commercially viable?
Yes; they target specific patient preferences and clinical needs, but require significant R&D and regulatory approval investment.

4. What are the main competing drugs?
Other antihypertensives like beta-blockers and ACE inhibitors, and alternative ADHD treatments, limit clonidine’s market share.

5. Is there potential in emerging markets?
Potential exists, but affordability and healthcare infrastructure constraints limit rapid growth.

---

Citations

[1] IQVIA. U.S. Prescription Drug Market Data, 2022.
[2] EvaluatePharma. Global clonidine sales, 2022.
[3] FDA Pharmaceuticals Approval and Market Reports.
[4] U.S. Patent and Trademark Office Records, 2010.